FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2159746057> ?p ?o ?g. }

• W2159746057 endingPage "1926" @default.
• W2159746057 startingPage "1919" @default.
• W2159746057 abstract "Purpose Most patients with acute myeloid leukemia (AML) eventually experience relapse. Relapsed/refractory AML has a dismal prognosis and currently available treatment options are generally ineffective. The objective of this large, international, randomized clinical trial was to investigate the efficacy of elacytarabine, a novel elaidic acid ester of cytarabine, versus the investigator's choice of one of seven commonly used AML salvage regimens, including high-dose cytarabine, multiagent chemotherapy, hypomethylating agents, hydroxyurea, and supportive care. Patients and Methods A total of 381 patients with relapsed/refractory AML were treated in North America, Europe, and Australia. Investigators selected a control treatment for individual patients before random assignment. The primary end point was overall survival (OS). Results There were no significant differences in OS (3.5 v 3.3 months), response rate (23% v 21%), or relapse-free survival (5.1 v 3.7 months) between the elacytarabine and control arms, respectively. There was no significant difference in OS among any of the investigator's choice regimens. Prolonged survival was only achieved in a few patients in both study arms whose disease responded and who underwent allogeneic stem-cell transplantation. Conclusion Neither elacytarabine nor any of the seven alternative treatment regimens provided clinically meaningful benefit to these patients. OS in both study arms and for all treatments was extremely poor. Novel agents, novel clinical trial designs, and novel strategies of drug development are all desperately needed for this patient population." @default.
• W2159746057 created "2016-06-24" @default.
• W2159746057 creator A5003572390 @default.
• W2159746057 creator A5003682435 @default.
• W2159746057 creator A5006999192 @default.
• W2159746057 creator A5007226852 @default.
• W2159746057 creator A5012863731 @default.
• W2159746057 creator A5014892222 @default.
• W2159746057 creator A5025780450 @default.
• W2159746057 creator A5042487507 @default.
• W2159746057 creator A5044188379 @default.
• W2159746057 creator A5046387225 @default.
• W2159746057 creator A5052288829 @default.
• W2159746057 creator A5053724616 @default.
• W2159746057 creator A5055227182 @default.
• W2159746057 creator A5061285204 @default.
• W2159746057 creator A5063374954 @default.
• W2159746057 creator A5078922292 @default.
• W2159746057 date "2014-06-20" @default.
• W2159746057 modified "2023-10-14" @default.
• W2159746057 title "International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia" @default.
• W2159746057 cites W1870350942 @default.
• W2159746057 cites W1982035148 @default.
• W2159746057 cites W1988758777 @default.
• W2159746057 cites W2018283978 @default.
• W2159746057 cites W2048591988 @default.
• W2159746057 cites W2068936693 @default.
• W2159746057 cites W2079541706 @default.
• W2159746057 cites W2095355543 @default.
• W2159746057 cites W2106084333 @default.
• W2159746057 cites W2112998845 @default.
• W2159746057 cites W2149058047 @default.
• W2159746057 cites W2157287007 @default.
• W2159746057 cites W2159507916 @default.
• W2159746057 cites W2170846829 @default.
• W2159746057 cites W24057889 @default.
• W2159746057 cites W4376595466 @default.
• W2159746057 doi "https://doi.org/10.1200/jco.2013.52.8562" @default.
• W2159746057 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24841975" @default.
• W2159746057 hasPublicationYear "2014" @default.
• W2159746057 type Work @default.
• W2159746057 sameAs 2159746057 @default.
• W2159746057 citedByCount "158" @default.
• W2159746057 countsByYear W21597460572014 @default.
• W2159746057 countsByYear W21597460572015 @default.
• W2159746057 countsByYear W21597460572016 @default.
• W2159746057 countsByYear W21597460572017 @default.
• W2159746057 countsByYear W21597460572018 @default.
• W2159746057 countsByYear W21597460572019 @default.
• W2159746057 countsByYear W21597460572020 @default.
• W2159746057 countsByYear W21597460572021 @default.
• W2159746057 countsByYear W21597460572022 @default.
• W2159746057 countsByYear W21597460572023 @default.
• W2159746057 crossrefType "journal-article" @default.
• W2159746057 hasAuthorship W2159746057A5003572390 @default.
• W2159746057 hasAuthorship W2159746057A5003682435 @default.
• W2159746057 hasAuthorship W2159746057A5006999192 @default.
• W2159746057 hasAuthorship W2159746057A5007226852 @default.
• W2159746057 hasAuthorship W2159746057A5012863731 @default.
• W2159746057 hasAuthorship W2159746057A5014892222 @default.
• W2159746057 hasAuthorship W2159746057A5025780450 @default.
• W2159746057 hasAuthorship W2159746057A5042487507 @default.
• W2159746057 hasAuthorship W2159746057A5044188379 @default.
• W2159746057 hasAuthorship W2159746057A5046387225 @default.
• W2159746057 hasAuthorship W2159746057A5052288829 @default.
• W2159746057 hasAuthorship W2159746057A5053724616 @default.
• W2159746057 hasAuthorship W2159746057A5055227182 @default.
• W2159746057 hasAuthorship W2159746057A5061285204 @default.
• W2159746057 hasAuthorship W2159746057A5063374954 @default.
• W2159746057 hasAuthorship W2159746057A5078922292 @default.
• W2159746057 hasBestOaLocation W21597460571 @default.
• W2159746057 hasConcept C104317684 @default.
• W2159746057 hasConcept C121332964 @default.
• W2159746057 hasConcept C126322002 @default.
• W2159746057 hasConcept C141071460 @default.
• W2159746057 hasConcept C142424586 @default.
• W2159746057 hasConcept C143998085 @default.
• W2159746057 hasConcept C150194340 @default.
• W2159746057 hasConcept C168563851 @default.
• W2159746057 hasConcept C185592680 @default.
• W2159746057 hasConcept C190727270 @default.
• W2159746057 hasConcept C203092338 @default.
• W2159746057 hasConcept C2776012956 @default.
• W2159746057 hasConcept C2776611710 @default.
• W2159746057 hasConcept C2776694085 @default.
• W2159746057 hasConcept C2777198975 @default.
• W2159746057 hasConcept C2778041864 @default.
• W2159746057 hasConcept C2778729363 @default.
• W2159746057 hasConcept C2908647359 @default.
• W2159746057 hasConcept C2911091166 @default.
• W2159746057 hasConcept C535046627 @default.
• W2159746057 hasConcept C55493867 @default.
• W2159746057 hasConcept C71924100 @default.
• W2159746057 hasConcept C87355193 @default.
• W2159746057 hasConcept C99454951 @default.
• W2159746057 hasConceptScore W2159746057C104317684 @default.
• W2159746057 hasConceptScore W2159746057C121332964 @default.
• W2159746057 hasConceptScore W2159746057C126322002 @default.

• next